Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Pathology in Practice.

Leisering AL, Sola MF, Ambrosius LA, Monahan CF, Meyer BA, Deshuillers PL, Durkes AC, Knapp DW, Sledge DG, Thompson CA.

J Am Vet Med Assoc. 2019 Aug 15;255(4):433-436. doi: 10.2460/javma.255.4.433. No abstract available.

PMID:
31355720
2.

Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model.

Chand D, Dhawan D, Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X.

Bladder Cancer. 2019 Jan 31;5(1):63-71. doi: 10.3233/BLC-180204.

3.

Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma.

Szigetvari NM, Dhawan D, Ramos-Vara JA, Leamon CP, Klein PJ, Ruple AA, Heng HG, Pugh MR, Rao S, Vlahov IR, Deshuillers PL, Low PS, Fourez LM, Cournoyer AM, Knapp DW.

Oncotarget. 2018 Dec 11;9(97):37042-37053. doi: 10.18632/oncotarget.26455. eCollection 2018 Dec 11.

4.
5.

Fatty Acid Patterns Detected By Ambient Ionization Mass Spectrometry in Canine Invasive Urothelial Carcinoma From Dogs of Different Breeds.

D'Hue CA, Dhawan D, Peat T, Ramos-Vara J, Jarmusch A, Knapp DW, Cooks RG.

Bladder Cancer. 2018 Jul 30;4(3):283-291. doi: 10.3233/BLC-170125.

6.

Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer.

Dhawan D, Hahn NM, Ramos-Vara JA, Knapp DW.

PLoS Genet. 2018 Aug 8;14(8):e1007571. doi: 10.1371/journal.pgen.1007571. eCollection 2018 Aug.

7.

Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma.

Ambrosius LA, Dhawan D, Ramos-Vara JA, Ruple A, Knapp DW, Childress MO.

Am J Vet Res. 2018 Jun;79(6):643-649. doi: 10.2460/ajvr.79.6.643.

PMID:
30085860
8.

Canine (Pet Dog) Tumor Microsurgery and Intratumoral Concentration and Safety of Metronomic Chlorambucil for Spontaneous Glioma: A Phase I Clinical Trial.

Bentley RT, Thomovsky SA, Miller MA, Knapp DW, Cohen-Gadol AA.

World Neurosurg. 2018 Aug;116:e534-e542. doi: 10.1016/j.wneu.2018.05.027. Epub 2018 Jun 5.

PMID:
29775768
9.

Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.

Sommer BC, Dhawan D, Ratliff TL, Knapp DW.

Bladder Cancer. 2018 Apr 26;4(2):149-159. doi: 10.3233/BLC-170145. Review.

10.

Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody.

Nagaya T, Okuyama S, Ogata F, Maruoka Y, Knapp DW, Karagiannis SN, Fazekas-Singer J, Choyke PL, LeBlanc AK, Jensen-Jarolim E, Kobayashi H.

Oncotarget. 2018 Apr 10;9(27):19026-19038. doi: 10.18632/oncotarget.24876. eCollection 2018 Apr 10.

11.

Evaluation of two-dimensional ultrasonography and computed tomography in the mapping and measuring of canine urinary bladder tumors.

Honkisz SI, Naughton JF, Weng HY, Fourez LM, Knapp DW.

Vet J. 2018 Feb;232:23-26. doi: 10.1016/j.tvjl.2017.12.008. Epub 2017 Dec 12.

PMID:
29428087
12.

Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.

Fulkerson CM, Dhawan D, Ratliff TL, Hahn NM, Knapp DW.

Int J Genomics. 2017;2017:6589529. doi: 10.1155/2017/6589529. Epub 2017 Apr 9. Review.

13.

Skeletal Metastasis of Canine Urothelial Carcinoma: Pathologic and Computed Tomographic Features.

Charney VA, Miller MA, Heng HG, Weng HY, Knapp DW.

Vet Pathol. 2017 May;54(3):380-386. doi: 10.1177/0300985816677152. Epub 2016 Nov 24.

PMID:
27879443
14.

Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder cancer multimodal imaging.

Key J, Dhawan D, Cooper CL, Knapp DW, Kim K, Kwon IC, Choi K, Park K, Decuzzi P, Leary JF.

Int J Nanomedicine. 2016 Aug 29;11:4141-55. doi: 10.2147/IJN.S109494. eCollection 2016.

15.

A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma.

Knapp DW, Ruple-Czerniak A, Ramos-Vara JA, Naughton JF, Fulkerson CM, Honkisz SI.

Bladder Cancer. 2016 Apr 27;2(2):241-250.

16.

Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.

LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, London C, Mason N, Mazcko C, Olson PN, Page R, Teicher BA, Thamm DH, Trent JM, Vail DM, Khanna C.

Sci Transl Med. 2016 Feb 3;8(324):324ps5. doi: 10.1126/scitranslmed.aaf0746. Review. No abstract available.

PMID:
26843188
17.

A cultured approach to canine urothelial carcinoma: molecular characterization of five cell lines.

Shapiro SG, Knapp DW, Breen M.

Canine Genet Epidemiol. 2015 Sep 17;2:15. doi: 10.1186/s40575-015-0028-3. eCollection 2015.

18.

Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer.

Dhawan D, Paoloni M, Shukradas S, Choudhury DR, Craig BA, Ramos-Vara JA, Hahn N, Bonney PL, Khanna C, Knapp DW.

PLoS One. 2015 Sep 9;10(9):e0136688. doi: 10.1371/journal.pone.0136688. eCollection 2015.

19.

Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs.

Fulkerson CM, Dhawan D, Jones DR, Marquez VE, Jones PA, Wang Z, Wu Q, Klaunig JE, Fourez LM, Bonney PL, Knapp DW.

Vet Comp Oncol. 2017 Mar;15(1):226-236. doi: 10.1111/vco.12159. Epub 2015 Jul 14.

PMID:
26178438
20.

"Lassie," "Toto," and fellow pet dogs: poised to lead the way for advances in cancer prevention.

Knapp DW, Dhawan D, Ostrander E.

Am Soc Clin Oncol Educ Book. 2015:e667-72. doi: 10.14694/EdBook_AM.2015.35.e667. Review.

21.

Canine urothelial carcinoma: genomically aberrant and comparatively relevant.

Shapiro SG, Raghunath S, Williams C, Motsinger-Reif AA, Cullen JM, Liu T, Albertson D, Ruvolo M, Bergstrom Lucas A, Jin J, Knapp DW, Schiffman JD, Breen M.

Chromosome Res. 2015 Jun;23(2):311-31. doi: 10.1007/s10577-015-9471-y. Epub 2015 Mar 18.

22.

Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.

Decker B, Parker HG, Dhawan D, Kwon EM, Karlins E, Davis BW, Ramos-Vara JA, Bonney PL, McNiel EA, Knapp DW, Ostrander EA.

Mol Cancer Res. 2015 Jun;13(6):993-1002. doi: 10.1158/1541-7786.MCR-14-0689. Epub 2015 Mar 12.

23.

Management of transitional cell carcinoma of the urinary bladder in dogs: a review.

Fulkerson CM, Knapp DW.

Vet J. 2015 Aug;205(2):217-25. doi: 10.1016/j.tvjl.2015.01.017. Epub 2015 Jan 26. Review.

PMID:
25747698
24.

Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development.

Knapp DW, Ramos-Vara JA, Moore GE, Dhawan D, Bonney PL, Young KE.

ILAR J. 2014;55(1):100-18. doi: 10.1093/ilar/ilu018. Review.

PMID:
24936033
25.

Assessment of folate receptor expression and folate uptake in multicentric lymphomas in dogs.

Childress MO, Dhawan D, Leamon CP, Miller MA, Ramos-Vara JA, Naughton JF, Low PS, Knapp DW.

Am J Vet Res. 2014 Feb;75(2):187-94. doi: 10.2460/ajvr.75.2.187.

PMID:
24471755
26.

Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma.

Schrempp DR, Childress MO, Stewart JC, Leach TN, Tan KM, Abbo AH, de Gortari AE, Bonney PL, Knapp DW.

J Am Vet Med Assoc. 2013 Jun 1;242(11):1534-8. doi: 10.2460/javma.242.11.1534.

PMID:
23683018
27.

Detection of herbicides in the urine of pet dogs following home lawn chemical application.

Knapp DW, Peer WA, Conteh A, Diggs AR, Cooper BR, Glickman NW, Bonney PL, Stewart JC, Glickman LT, Murphy AS.

Sci Total Environ. 2013 Jul 1;456-457:34-41. doi: 10.1016/j.scitotenv.2013.03.019. Epub 2013 Apr 10.

PMID:
23584031
28.

Characterization and treatment of transitional cell carcinoma of the abdominal wall in dogs: 24 cases (1985-2010).

Higuchi T, Burcham GN, Childress MO, Rohleder JJ, Bonney PL, Ramos-Vara JA, Knapp DW.

J Am Vet Med Assoc. 2013 Feb 15;242(4):499-506. doi: 10.2460/javma.242.4.499.

PMID:
23363282
29.

Outcome of urethral stent placement for management of urethral obstruction secondary to transitional cell carcinoma in dogs: 19 cases (2007-2010).

McMillan SK, Knapp DW, Ramos-Vara JA, Bonney PL, Adams LG.

J Am Vet Med Assoc. 2012 Dec 15;241(12):1627-32. doi: 10.2460/javma.241.12.1627.

PMID:
23216038
30.

Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder.

Knapp DW, Henry CJ, Widmer WR, Tan KM, Moore GE, Ramos-Vara JA, Lucroy MD, Greenberg CB, Greene SN, Abbo AH, Hanson PD, Alva R, Bonney PL.

J Vet Intern Med. 2013 Jan-Feb;27(1):126-33. doi: 10.1111/jvim.12013. Epub 2012 Dec 3.

31.

Targeting folate receptors to treat invasive urinary bladder cancer.

Dhawan D, Ramos-Vara JA, Naughton JF, Cheng L, Low PS, Rothenbuhler R, Leamon CP, Parker N, Klein PJ, Vlahov IR, Reddy JA, Koch M, Murphy L, Fourez LM, Stewart JC, Knapp DW.

Cancer Res. 2013 Jan 15;73(2):875-84. doi: 10.1158/0008-5472.CAN-12-2101. Epub 2012 Nov 29.

32.

Accuracy of three-dimensional and two-dimensional ultrasonography for measurement of tumor volume in dogs with transitional cell carcinoma of the urinary bladder.

Naughton JF, Widmer WR, Constable PD, Knapp DW.

Am J Vet Res. 2012 Dec;73(12):1919-24. doi: 10.2460/ajvr.73.12.1919.

PMID:
23176418
33.

Cutaneous metastasis of transitional cell carcinoma in 12 dogs.

Reed LT, Knapp DW, Miller MA.

Vet Pathol. 2013 Jul;50(4):676-81. doi: 10.1177/0300985812465326. Epub 2012 Nov 6.

PMID:
23136183
34.

NMR-based metabolomics study of canine bladder cancer.

Zhang J, Wei S, Liu L, Nagana Gowda GA, Bonney P, Stewart J, Knapp DW, Raftery D.

Biochim Biophys Acta. 2012 Nov;1822(11):1807-14. doi: 10.1016/j.bbadis.2012.08.001. Epub 2012 Aug 8.

35.

In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles.

Key J, Cooper C, Kim AY, Dhawan D, Knapp DW, Kim K, Park JH, Choi K, Kwon IC, Park K, Leary JF.

J Control Release. 2012 Oct 28;163(2):249-55. doi: 10.1016/j.jconrel.2012.07.038. Epub 2012 Aug 11.

PMID:
22902594
36.

DNMT1: an emerging target in the treatment of invasive urinary bladder cancer.

Dhawan D, Ramos-Vara JA, Hahn NM, Waddell J, Olbricht GR, Zheng R, Stewart JC, Knapp DW.

Urol Oncol. 2013 Nov;31(8):1761-9. doi: 10.1016/j.urolonc.2012.03.015. Epub 2012 May 19.

PMID:
22609058
37.

Ultrasound-guided endoscopic diode laser ablation in dogs with transitional cell carcinoma.

Knapp DW.

J Am Vet Med Assoc. 2012 Apr 1;240(7):802; author reply 802-3. doi: 10.2460/javma.240.7.802. No abstract available.

PMID:
22443431
38.

Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer.

Leach TN, Childress MO, Greene SN, Mohamed AS, Moore GE, Schrempp DR, Lahrman SR, Knapp DW.

Vet Comp Oncol. 2012 Jun;10(2):102-12. doi: 10.1111/j.1476-5829.2011.00280.x. Epub 2011 Sep 9.

PMID:
22236329
39.

Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development.

Hahn NM, Bonney PL, Dhawan D, Jones DR, Balch C, Guo Z, Hartman-Frey C, Fang F, Parker HG, Kwon EM, Ostrander EA, Nephew KP, Knapp DW.

J Urol. 2012 Jan;187(1):302-9. doi: 10.1016/j.juro.2011.09.010. Epub 2011 Nov 17.

40.

Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder.

Arnold EJ, Childress MO, Fourez LM, Tan KM, Stewart JC, Bonney PL, Knapp DW.

J Vet Intern Med. 2011 Nov-Dec;25(6):1385-90. doi: 10.1111/j.1939-1676.2011.00796.x. Epub 2011 Sep 13.

41.

Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder.

McMillan SK, Boria P, Moore GE, Widmer WR, Bonney PL, Knapp DW.

J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9. doi: 10.2460/javma.239.8.1084.

PMID:
21985349
42.

Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours.

Sonzogni-Desautels K, Knapp DW, Sartin E, Doré M.

Vet Comp Oncol. 2011 Sep;9(3):161-71. doi: 10.1111/j.1476-5829.2010.00242.x. Epub 2010 Aug 26.

PMID:
21848619
43.

Results of biopsy via transurethral cystoscopy and cystotomy for diagnosis of transitional cell carcinoma of the urinary bladder and urethra in dogs: 92 cases (2003-2008).

Childress MO, Adams LG, Ramos-Vara JA, Freeman LJ, He S, Constable PD, Knapp DW.

J Am Vet Med Assoc. 2011 Aug 1;239(3):350-6. doi: 10.2460/javma.239.3.350.

PMID:
21801049
44.

Cancer prevention interdisciplinary education program at Purdue University: overview and preliminary results.

Teegarden D, Lee JY, Adedokun O, Childress A, Parker LC, Burgess W, Nagel J, Knapp DW, Lelievre S, Agnew CR, Shields C, Leary J, Adams R, Jensen JD.

J Cancer Educ. 2011 Dec;26(4):626-32. doi: 10.1007/s13187-011-0232-0.

45.

Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder.

Abbo AH, Jones DR, Masters AR, Stewart JC, Fourez L, Knapp DW.

J Vet Intern Med. 2010 Sep-Oct;24(5):1124-30. doi: 10.1111/j.1939-1676.2010.0569.x. Epub 2010 Jul 28.

46.

Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder.

Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, Stewart JC, Zheng R, Loman RA, Foster RS, Knapp DW.

Mol Cancer Ther. 2010 May;9(5):1371-7. doi: 10.1158/1535-7163.MCT-10-0049. Epub 2010 Apr 27.

47.

Lipid profiles of canine invasive transitional cell carcinoma of the urinary bladder and adjacent normal tissue by desorption electrospray ionization imaging mass spectrometry.

Dill AL, Ifa DR, Manicke NE, Costa AB, Ramos-Vara JA, Knapp DW, Cooks RG.

Anal Chem. 2009 Nov 1;81(21):8758-64. doi: 10.1021/ac901028b.

48.

Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats.

Greene SN, Ramos-Vara JA, Craig BA, Hooser SB, Anderson C, Fourez LM, Johnson BM, Stewart JC, Knapp DW.

Cancer Chemother Pharmacol. 2010 Feb;65(3):549-56. doi: 10.1007/s00280-009-1061-2. Epub 2009 Jul 23.

PMID:
19629487
49.

Glycoproteomic profiling of serum peptides in canine lymphoma and transitional cell carcinoma.

Wilson CR, Regnier FE, Knapp DW, Raskin RE, Andrews DA, Hooser SB.

Vet Comp Oncol. 2008 Sep;6(3):171-81. doi: 10.1111/j.1476-5829.2008.00158.x.

PMID:
19178677
50.

Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma.

Rankin WV, Henry CJ, Turnquist SE, Turk JR, Beissenherz ME, Tyler JW, Rucker EB, Knapp DW, Rodriguez CO, Green JA.

Vet Comp Oncol. 2008 Sep;6(3):141-50. doi: 10.1111/j.1476-5829.2007.00150.x.

PMID:
19178674

Supplemental Content

Loading ...
Support Center